

One-pot Synthesis of α -Aminophosphonates via Cascade

Sequence of Allylamine Isomerization/Hydrophosphonylation

Liu-Liang Mao,^{+, a} Chen-Chen Li,^{+, a} Qiang Yang,^a Ming-Xing Cheng,^a Shang-Dong Yang^{a, b*}

^aState Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, P. R. China.

^bState Key Laboratory for Oxo Synthesis and Selective Oxidation, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou, 730000, P. R. China.

Contents:

1. General information	2
2. Optimization reaction conditions	2
3. The experimental procedure	4
4. The preparation of the substrate 1a-d , 2a-d and 1a-Nd	4
5. Preliminary mechanistic studies	8
6. Procedure for desulfonylation and Hydrolysis reaction of 6aa	11
7. Synthesis of hFPPS 9a	12
8. References	14
9. Characterization data of products	14
10. Copies of NMR spectra	25


1. General information.

^1H and ^{13}C NMR spectra were recorded on a Bruker advance III400 spectrometer (400 MHz for ^1H and 100 MHz for ^{13}C) in CDCl_3 with TMS as internal standard. Chemical shifts (δ) were measured in ppm relative to TMS $\delta = 0$ for ^1H , or to chloroform $\delta = 77.0$ for ^{13}C as internal standard. ^{31}P NMR spectra and ^{19}F NMR were recorded on the same instrument. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants, J are reported in hertz. High-resolution mass spectral analysis (HRMS) data were measured on a Bruker ApexII mass spectrometer by means of the ESI technique, a Bruker maXis 4G mass spectrometer by means of the ESI-TOF technique or the Orbitrap Elite mass spectrometer by means of the ESI technique. The starting materials were purchased from Aldrich, Acros Organics, J&K Chemicals Adamas-beta or TCI and used without further purification. Solvents were dried and purified according to the procedure from "Purification of Laboratory Chemicalsbook". Thin-layer chromatography (TLC) was performed using 60 mesh silica gel plates visualized with short-wavelength UV light (254 nm). Substituted allylamines were prepared according to the literature procedure.^[S1]

2. Optimization reaction conditions

2-1. Optimization reaction conditions of Rh-Catalyzed Allylamine Isomerization/Hydrophosphonylation.^[a]


Table S1. Reaction Conditions Screening



Reaction scheme: $\text{CH}_2=\text{CH}-\text{CH}_2-\text{NH}-\text{Ph}$ (1a) + $\text{H}-\text{P}(\text{O})(\text{Ph})_2$ (2a) $\xrightarrow[\text{solvent, } 60\text{ }^\circ\text{C}]{\text{catalyst, additive, ligand}}$ $\text{CH}_3-\text{CH}_2-\text{CH}_2-\text{NH}-\text{Ph}$ (3aa) with $-\text{P}(\text{O})(\text{Ph})_2$ group on the β -carbon.

entry	solvent	catalyst	additive	ligand	time (h)	yield (%) ^[b]
1	PhMe	$[\text{Rh}(\text{COD})\text{Cl}]_2$	Ag_2CO_3		20	91
2	DMF	$[\text{Rh}(\text{COD})\text{Cl}]_2$	Ag_2CO_3		20	trace
3	THF	$[\text{Rh}(\text{COD})\text{Cl}]_2$	Ag_2CO_3		20	92
4	MeCN	$[\text{Rh}(\text{COD})\text{Cl}]_2$	Ag_2CO_3		20	0
5	i-PrOH	$[\text{Rh}(\text{COD})\text{Cl}]_2$	Ag_2CO_3		20	72
6	dioxane	$[\text{Rh}(\text{COD})\text{Cl}]_2$	Ag_2CO_3		16	97
7	dioxane	$[\text{Rh}(\text{COD})\text{Cl}]_2$	Ag_2CO_3	L1	16	96 (race)
8	dioxane	$[\text{Rh}(\text{COD})\text{Cl}]_2$	Ag_2CO_3	L2	16	97 (race)
9	dioxane	$[\text{Rh}(\text{COD})\text{Cl}]_2$	Ag_2CO_3	L3	16	84 (race)
10	dioxane	$[\text{Rh}(\text{COD})\text{Cl}]_2$	Ag_2CO_3	L4	16	97 (race)
11	dioxane		Ag_2CO_3		16	0
12	dioxane	$[\text{Rh}(\text{COD})\text{Cl}]_2$			16	88
13	dioxane	$[\text{Rh}(\text{COD})\text{Cl}]_2$	AgOTf		16	33
14	dioxane	$[\text{Rh}(\text{COD})\text{Cl}]_2$	AgNO_3		16	0
15	dioxane	$[\text{Rh}(\text{COD})\text{Cl}]_2$	Ag_3PO_4		16	0

16	dioxane	[Rh(COD)Cl] ₂	AgBF ₄	16	66
17	dioxane	[Rh(COD)Cl] ₂	AgClO ₄	16	54
18	dioxane	[Rh(COD)Cl] ₂	AgCl	16	95
19	dioxane	[Rh(COD)Cl] ₂	Na ₂ CO ₃	16	84
20	dioxane	[Rh(COD)Cl] ₂	K ₂ CO ₃	16	80
21	dioxane	[Rh(COD)Cl] ₂	NaHCO ₃	16	94




[a] The reaction was carried out with [M] 2.5 mol %, additive 20 mol %, **1a** (0.20 mmol), and **2a** (1.5 equiv.) in solvent (1.0 mL) at 60 °C under argon, unless otherwise noted. [b] Yield of isolated product.

Note: we tried to add some kinds of ligands in this reaction system (entries 7-10; Table S1). However, we find that ligand did not play an important role in this reaction.

2-2. Optimization reaction conditions of Ni-Catalyzed Allylamine Isomerization/Hydrophosphonylation.^{[a] [S2]}

Table S2. Reaction Conditions Screening



entry	solvent	catalyst	base	ligand	yield (%) ^[b]
1	dioxane	Ni(PPh ₃) ₂ Cl ₂	K ₃ PO ₄		49
2	THF	Ni(PPh ₃) ₂ Cl ₂	K ₃ PO ₄		47
3	DMF	Ni(PPh ₃) ₂ Cl ₂	K ₃ PO ₄		82
4	Et ₂ O	Ni(PPh ₃) ₂ Cl ₂	K ₃ PO ₄		40
5	DME	Ni(PPh ₃) ₂ Cl ₂	K ₃ PO ₄		67
6	toluene	Ni(PPh ₃) ₂ Cl ₂	K ₃ PO ₄		0
7	DMF	Ni(PPh ₃) ₂ Cl ₂	CS ₂ CO ₃		47
8	DMF	Ni(PPh ₃) ₂ Cl ₂	K ₂ CO ₃		15
9	DMF	Ni(PPh ₃) ₂ Cl ₂	DABCO		trace
10	DMF	Ni(PPh ₃) ₂ Cl ₂	Et ₃ N		trace
11	DMF	Ni(PPh ₃) ₂ Cl ₂	DMAP		0
12	DMF	Ni(PPh ₃) ₂ Cl ₂			0

13	DMF	NiCl ₂	K ₃ PO ₄	PPh ₃	86
14	DMF	NiCl₂	K₃PO₄		90
15	DMF	Ni(PCy ₃) ₂ Cl ₂	K ₃ PO ₄		70
16	DMF	Ni(COD) ₂	K ₃ PO ₄		44
17	DMF	Ni(dppe)Cl ₂	K ₃ PO ₄		78
18	DMF	NiBr ₂	K ₃ PO ₄		87
19	DMF	Ni(OAc) ₂	K ₃ PO ₄		83
20	DMF	Ni(OTf) ₂	K ₃ PO ₄		65
21	DMF	Ni(ClO ₄) ₂	K ₃ PO ₄		88
22	DMF	Ni(acac) ₂	K ₃ PO ₄		69
23 ^[c]	DMF	NiCl ₂	K ₃ PO ₄		0
24 ^[d]	DMF	NiCl ₂	K ₃ PO ₄		70
25 ^[e]	DMF	NiCl ₂	K ₃ PO ₄		68
26 ^[f]	DMF	NiCl ₂	K ₃ PO ₄		60
26 ^[g]	DMF	NiCl ₂	K ₃ PO ₄		85
27	DMF	Ni(<i>R</i> -Binap)Cl ₂	K ₃ PO ₄		84 (race)
28	DMF	NiCl ₂	K ₃ PO ₄	<i>R</i> -Binap	40 (race)

[a] The reaction was carried out with catalyst 5 mol %, Base 120 mol %, **4a** (0.20 mmol), and **5a** (1.5 equiv.) in solvent (1.0 mL) at 60 °C under argon, unless otherwise noted. [b] Yield of isolated product. [c] Under air. [d] at 40 °C. [e] at 80 °C. [f] catalyst 2 mol %. [g] catalyst 10 mol %.

3. The experimental procedure

3.1 Rh-Catalyzed Allylamine Isomerization/Hydrophosphonylation.

In a Schlenk tube, *N*-allylaniline (0.20 mmol), [Rh(cod)Cl]₂ (2.5 mol %), Ag₂CO₃ (20 mol %), HP(O)Ph₂ (0.30 mmol) were added and charged with Ar three times. Then anhydrous Dioxane (1.0 mL) was added. The mixture was allowed to stir at 60 °C for 16 hours (monitored by TLC). After substrate was consumed, the reaction was cooled to room temperature and concentrated in vacuo, and the resulting residue was purified by column chromatography to give **3aa** in 97% yield (PE : EA = 3 : 1, then PE : *i*-PrOH = 20 : 1).


3.2 Ni-Catalyzed Allylamine Isomerization/Hydrophosphonylation.

In a Schlenk tube, *N*-allyl-4-methylbenzenesulfonamide (0.20 mmol), NiCl₂ (5 mol %), K₃PO₄ (120 mol %), diethyl phosphonate (0.30 mmol) were added and charged with Ar three times. Then, anhydrous DMF (1.0 mL) were added. The mixture was allowed to stir at 60 °C for 10 hours (monitored by TLC). After substrate was consumed, the reaction was cooled to room temperature, 5 mL H₂O and 10 mL DCM was added, then the organic layer was separated and aqueous layer was extracted with DCM (10 mL × 2), The combined organic layer was washed with brine and dried over anhydrous Na₂SO₄ then concentrated in vacuo, and the resulting residue was purified by

column chromatography to give **6aa** in 90% yield (PE : EA = 3 : 1, then PE : *i*-PrOH = 20 : 1).

4. The preparation of the substrate **1a-d**, **2a-d** and **1a-Nd**

4-1 synthesis of **1a-d**.^[S3]



Scheme S1. Synthesis of **1a-d**

1,1-Dideuterioallyl alcohol:

Under an argon atmosphere, LiAlD_4 (0.5 g, 11.9 mmol) and anhydrous ether (20 mL) were added into a 50 mL flame-dried flask fitted with magnetic stirrer bar at $-10\text{ }^\circ\text{C}$. Then, a solution of acryloyl chloride (1.5 mL, 17.8 mmol) in ether was added dropwise over 10 min. The resulting mixture was warmed to room temperature slowly and stirred for 10 h. The mixture was cooled to $-10\text{ }^\circ\text{C}$ and H_2O (1.0 mL) was slowly added over a 5 min period. After stirring for another 15 min, 15% aqueous NaOH solution (1.0 mL) and then H_2O (1.0 mL) were added. The resulting slurry was stirred for 1 h and then filtered. The filtrate was dried over Na_2SO_4 . The solvent was removed carefully on a rotary evaporator (atmospheric pressure, $37\text{ }^\circ\text{C}$) to afford a colorless liquid, which was used in the next step without further purification. $^1\text{H NMR}$ (400 MHz, CDCl_3): 6.01 (1 H, dd), 5.20 (2 H, m).

1,1-Dideuterioallyl tosyl ester:

A 50 mL Schlenk flask was charged with 1,1-dideuterioallyl alcohol (0.5 g, 8.2 mmol, crude product from previous step), tosyl chloride (1.6 g, 8.3 mmol) and anhydrous ether (10 mL). The mixture was cooled to $0\text{ }^\circ\text{C}$ and powdered NaOH (0.9 g, 22.5 mmol) was added in portions under N_2 . The reaction was then warmed to room temperature and stirred for 12 h. The precipitate was filtered and the filtrate concentrated in vacuo. The resulting oil was subjected to column chromatography (silica gel, 90:10 hexane/ EtOAc) to the yield pure product (1.5 g, 88%). $^1\text{H NMR}$ (300 MHz, CDCl_3): 7.80 (2 H, d), 7.33 (2 H, d), 5.81 (1 H, dd), 5.28 (1 H, d), 5.16 (1 H, d), 2.46 (3 H, s).

N-1-(1,1-Dideuterioallyl)allylaniline (**1a-d**)

To a 25 mL Schlenk flask under Ar atmosphere were successively charged, the PhNH_2 (4.0 equiv), K_2CO_3 (1.1 equiv) and dry MeCN (2.0 mL). Then, the resulting mixture was heated for 10 min at $60\text{ }^\circ\text{C}$ in a preheated oil bath before dropwise addition of 1,1-Dideuterioallyl tosyl ester (1.0 equiv) diluted in dry MeCN (2.0 mL). The resulting mixture was stirred for 20 h at $60\text{ }^\circ\text{C}$. The water was added to quench the reaction, 10 mL EtOAc was added, then the organic layer was separated and aqueous layer was extracted with EtOAc (10 mL \times 2). The combined organic layer was washed with brine and dried over anhydrous Na_2SO_4 then concentrated in vacuo, and the resulting residue was purified by column chromatography to give **1a-d** in 58% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) 7.18 (dd, $J = 16.7, 9.1\text{ Hz}$, 2H), 6.74 - 6.65 (m, 1H), 6.61 (d, $J = 8.0\text{ Hz}$, 2H), 5.93 (dt, $J = 20.7,$

10.3 Hz, 1H), 5.19 (dt, J = 44.8, 25.8 Hz, 2H), 4.05 - 3.26 (m, 1H), **MS : m/z (M+H):** 136.1088.





Figure S1. ^1H NMR spectra of **1a-d**

4-2 synthesis of **2a-d**



An oven dried flask (50 mL) was charged with diphenylphosphine oxide (404 mg, 2 mmol) and dried THF (15 mL) at $-78\text{ }^\circ\text{C}$. Then, n-BuLi (2.5 equiv) was added over 5 min, the resulting mixture was warmed to $-50\text{ }^\circ\text{C}$ slowly and stirred for 1 h. The mixture was cooled to $-78\text{ }^\circ\text{C}$ and D_2O (10 equiv) was slowly added slowly and the mixture was stirred for 1 h and then filtered. The filtrate was dried over MgSO_4 . The solvent was removed on a rotary evaporator to afford **2a-d** in 100% yield. ^1H NMR (400 MHz, CDCl_3) 8.69 (s, 0.08H), 7.77 - 7.64 (m, 4H), 7.58 (m, 2H), 7.54 - 7.43 (m, 4H), 7.28 (s, 0.08H).






Figure S2. ^1H NMR spectra of **2a-d**

4-3 synthesis of **1a-Nd**




N-allylaniline (200 μL) was stirred in D_2O (4.0 mL) at $50\text{ }^\circ\text{C}$ for 14 h, and then the solution was extracted with dry ether (20 mL \times 3). The combine organic extracts were dried and evaporated to give **1a-Nd** (>99% D).



5. Preliminary mechanistic studies

5.1 Radicals Trapping Experiments using BHT


In a Schlenk tube, *N*-allylaniline (0.20 mmol), [Rh(cod)Cl]₂ (2.5 mol %), Ag₂CO₃ (20 mol %), HP(O)Ph₂ (0.30 mmol) and BHT (2.0 equiv) were added and charged with Ar three times. Then, anhydrous Dioxane (1.0 mL) were added. The mixture was allowed to stir at 60 °C for 16 hours (monitored by TLC). After substrate was consumed, the reaction was cooled to room temperature and concentrated in vacuo, and the resulting residue was purified by column chromatography to give **3aa** in 97% yield (Scheme S2).








Scheme S2. Radicals Trapping Experiments using BHT



5.2 Deuterium labeling experiment of Rh-Catalyzed Allylamine Isomerization/Hydrophosphonylation.



In a Schlenk tube, *N*-allylaniline (deuterated *N*-allylaniline) (0.20 mmol), [Rh(cod)Cl]₂ (2.5 mol %), Ag₂CO₃ (20 mol %), HP(O)Ph₂ (deuterated HP(O)Ph₂) (0.30 mmol) or D₂O (3.0 equiv) were added and charged with Ar three times. Then, anhydrous Dioxane (1.0 mL) was added. The mixture was allowed to stir at 60 °C for 16 hours (monitored by TLC). After substrate was consumed, the reaction was cooled to room temperature and concentrated in vacuo, and the resulting residue was purified by column chromatography to give deuterated product. (Scheme S3). The products were under ¹H-NMR analysis.



Scheme S3. Deuterium labeling experiment








Note: compare the standard ^1H NMR with the ^1H NMR of N-H deuterated product.

5.3 Experimental procedure for the kinetic isotope effect (KIE) study of Rh-Catalyzed Allylamine Isomerization/Hydrophosphonylation^[S4].



Scheme S4. The kinetic isotope effect (KIE) study

In two different Schlenk tube, **1a** (0.30 mmol) or **1a-d** (0.30 mmol), [Rh(cod)Cl]₂ (2.5 mol %), Ag₂CO₃ (20 mol %), HP(O)Ph₂ **2a** (0.45 mmol) were added and charged with Ar three times. Then, anhydrous dioxane (2.0 mL) was added. The mixture was allowed to stir at 60 °C, The conversions of the reaction were measured carefully after designated time by ¹H NMR using 4-Iodotoluene (10 mg) as an internal standard.





Figure S3 Reaction conversions over time between **1a**(**1a-d**) and diphenylphosphine oxide
 $K_H/K_D=0.56/0.3467=1.62$

6. Procedure for desulfonylation and Hydrolysis reaction of **6aa**^[S5]


A suspension of α -aminophosphonate **6aa** (349 mg, 1.0 mmol) in HCl (10 M aq., 4 mL) was heated at reflux overnight. The resulting solution was concentrated under vacuum, the residue was dissolved in hot EtOH (2 mL), and an excess of propylene oxide was added to this solution. The mixture was stirred for 3 h at room temperature, and the resulting white solid was collected by filtration to give α -aminophosphonic acid **7a** (80 mg, 58%) (Scheme S5).



Scheme S5. Procedure for desulfonylation and Hydrolysis reaction of **6aa**

(1-aminopropyl)phosphonic acid (**7a**) (58%) White solid; ¹H NMR (400 MHz, D₂O) δ 3.1 – 3.12 (m, 1H), 2.14 – 1.91 (m, 1H), 1.90 – 1.67 (m, 1H), 1.13 (t, $J = 7.5$ Hz, 3H). ¹³C NMR (101 MHz, D₂O) δ 50.8 (d, $J = 143.2$ Hz), 21.82, 10.2 (d, $J = 9.4$ Hz). ³¹P NMR (162 MHz, D₂O) δ 13.48. MS : m/z (M+H): 140.0621.

7. Synthesis of Allosteric Inhibitors of hFPPS **9a**^[S6]



Scheme S6. Synthesis of Allosteric Inhibitors of hFPPS **9a**

6-Bromothieno[2,3-d]pyrimidin-4(3H)-one (**2**).

Thieno[2,3-d]pyrimidin-4(3H)-one (**1**) (0.78 g, 5 mmol) was mixed with acetic acid (12 mL), and bromine (0.52 mL, 1.6 g, 10 mmol) was added slowly before the mixture was heated at 80 °C for 3 h. The reaction mixture was then cooled to rt and filtered to remove insoluble components. The liquid fraction was diluted with ice and neutralised using a saturated aq NaHCO₃ solution. The precipitated material was isolated by filtration and washed with water (3×30 mL). Drying gave 1.03 g (4.4 mmol, 88%) of **2** as a light brown solid, ¹H NMR (400 MHz, DMSO) δ 12.63 (s, 1H), 8.17 (s, 1H), 7.54 (s, 1H). ¹³C NMR (101 MHz, DMSO) δ 165.4, 156.5, 146.9, 126.0, 125.0, 110.7. MS : m/z : 229.91.

6-Bromo-4-chlorothieno[2,3-d]pyrimidine (**3**)

Compound **2** (0.93 g, 4 mmol) was mixed with POCl₃ (3 mL) and heated at 120 °C for 10 h. Then the mixture was quenched into 5 M aq NaOH (30 mL) and ice. The pH was adjusted to 7 using a saturated aq NaHCO₃ solution. The formed precipitate was isolated by filtration and washed with water (3×15 mL). Drying gave 0.9 g (3.6 mmol, 90%) of **3** as a brown solid. ¹H NMR (400 MHz, DMSO) δ 9.05 – 8.70 (m, 1H), 7.83 (d, *J* = 4.4 Hz, 1H). ¹³C NMR (101 MHz, DMSO) δ 169.3, 153.6, 152.9, 130.6, 123.2, 118.9. MS : m/z : 247.88.

N-allyl-6-bromothieno[2,3-d]pyrimidin-4-amine (**4**)

Compound **3** (0.5 g, 2.0 mmol) was mixed with the Allylamine (3.5 equiv.) and *i*-PrOH (5 mL) and heated at 80 °C for 24 h, under nitrogen atmosphere. Then the mixture was cooled to rt, concentrated in vacuo, diluted with water (30 mL) and diethyl ether (30 mL). After phase separation, the water phase was extracted with more diethyl ether (2 × 30 mL). The combined organic phases were washed with saturated aq NaCl solution (2×30 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The resulting residue was purified by column chromatography to give 0.48 g (1.79 mmol, 89%) of **4** as a white solid (PE : EA = 10 : 1). ¹H NMR (400 MHz, DMSO) δ 8.31 (s, 1H), 8.19 (t, *J* = 5.4 Hz, 1H), 7.83 (s, 1H), 6.08 – 5.80 (m, 1H), 5.28 – 4.96 (m, 2H), 4.28 – 3.96 (m, 2H). ¹³C NMR (101 MHz, DMSO) δ 166.8, 155.9, 154.6, 135.4, 123.0, 117.3, 116.1, 110.0, 42.7. MS : m/z : 268.90.

N-allyl-6-(p-tolyl)thieno[2,3-d]pyrimidin-4-amine (**8a**)

Compound **4** (270 mg) was mixed with (4-methylphenyl)boronic acid (1.2 equiv), fine powdered K_2CO_3 (3 eq), $Pd(PPh_3)_4$ (10 mol %) and 1,4-dioxane/water (1/1 by vol. %, 4 mL). The reaction was then stirred at 80 °C for 20 h under nitrogen atmosphere. The solvent was removed and the product was diluted with water (30 mL) and extracted with Et_2O (30 mL), the water phase was extracted with more Et_2O (2×30 mL). The combined organic phases were washed with saturated aq NaCl solution (30 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated in vacuo. And the resulting residue was purified by column chromatography to give 259 mg (0.92 mmol, 92%) of **8a** as a light yellow solid (PE : EA = 8 : 1). 1H NMR (400 MHz, DMSO) δ 8.33 (s, 1H), 8.11 (t, J = 5.5 Hz, 1H), 7.99 (s, 1H), 7.55 (d, J = 8.1 Hz, 2H), 7.29 (d, J = 7.9 Hz, 2H), 5.99 (m, 1H), 5.19 (m, 2H), 4.17 (t, J = 5.4 Hz, 2H), 2.35 (d, J = 11.6 Hz, 3H). ^{13}C NMR (101 MHz, DMSO) δ 165.2, 156.8, 154.2, 138.8, 138.6, 135.6, 130.9, 130.3, 125.9, 118.0, 116.1, 115.0, 42.8, 21.2. MS : m/z : 281.05.

Diethyl (1-((6-(p-tolyl)thieno[2,3-d]pyrimidin-4-yl)amino)propyl)phosphonate (**9a**)

In a Schlenk tube, Compound **8a** (0.20 mmol), $NiCl_2$ (5 mol %), K_3PO_4 (120 mol %), diethyl phosphonate (0.30 mmol) were added and charged with Ar three times. Then, anhydrous DMF (1.0 mL) were added. The mixture was allowed to stir at 60 °C for 10 hours (monitored by TLC). After substrate was consumed, the reaction was cooled to room temperature, 5 mL H_2O and 10 mL DCM was added, then the organic layer was separated and aqueous layer was extracted with DCM (10 mL × 2), The combined organic layer was washed with brine and dried over anhydrous Na_2SO_4 then concentrated in vacuo, and the resulting residue was purified by column chromatography to give 36 mg (0.086 mmol, 43%) of **9a** as a white solid (PE : EA = 4 : 1, then PE : *i*-PrOH = 25 : 1). 1H NMR (400 MHz, $CDCl_3$) δ 8.46 (s, 1H), 7.56 (d, J = 6.2 Hz, 3H), 7.22 (d, J = 7.9 Hz, 2H), 6.23 (d, J = 9.6 Hz, 1H), 5.33 – 4.83 (m, 1H), 4.35 – 3.87 (m, 4H), 2.39 (s, 3H), 2.20 – 1.96 (m, 1H), 1.97 – 1.72 (m, 1H), 1.32 (t, J = 7.0 Hz, 3H), 1.16 (t, J = 7.0 Hz, 3H), 1.05 (t, J = 7.3 Hz, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 166.1, 156.6, 156.5, 153.4, 141.2, 138.7, 130.8, 129.7, 126.2, 118.0, 112.2, 63.0 (d, J = 7.0 Hz), 62.3 (d, J = 7.2 Hz), 47.6 (d, J = 155.3 Hz), 23.4, 21.2, 16.4 (d, J = 6.1 Hz), 10.6 (d, J = 13.1 Hz). ^{31}P NMR (162 MHz, $CDCl_3$) δ 24.98. MS : m/z (M+H): 420.1671.


8. Reference:

- [S1] (a) W. Martnez, G. Militao, T. Silva, R. Silva and P. Menezes, *RSC Adv.*, 2014, **4**, 14715; (b) G. Hoang, Z. Yang, S. Smith, R. Pal, J. Miska, D. Perez, L. Pelter, X. Zeng and J. Takacs, *Org. Lett.*, 2015, **17**, 940; (c) J. Johnson, J. Luo, X. Zhang, Y. Chen, M. Morton, E. Echeverr á, F. Torres and J. Zhang, *ACS Catal.*, 2015, **5**, 5283; (d) S. Sullivan, E. Doni, T. Tuttle and J. Murphy, *Angew. Chem. Int. Ed.* 2014, **53**, 474; (e) H. Wang, Y. Wang, D. Liang, L. Liu, J. Zhang and Q. Zhu, *Angew. Chem. Int. Ed.* 2011, **50**, 5678; (f) H. Clavier, A. Lepronier, N. Mintsá, D. Gatineau, H. Pellissier, L. Giordano, A. Tenaglia and G. Buono, *Adv. Synth. Catal.* 2013, **355**, 403; (g) S. Robin and G. Rousseau, *Eur. J. Org. Chem.* 2000, 3007; (h) X. Zhang, B. Cao, S. Yu and X. Zhang, *Angew. Chem. Int. Ed.* 2010, **49**, 4047.
- [S2] E. Standley, S. Smith, P. Müller and T. Jamison, *Organometallics*, 2014, **33**, 2012.
- [S3] (a) I. Dubovyk, I. D. G. Watson and A. K. Yudin, *J. Org. Chem.*, 2013, **78**, 1559; (b) D. S. Tsang, S. Yang, F.-A. Alphonse and A. K. Yudin, *Chem. Eur. J.* 2008, **14**, 886; (c) E. Forcellini, R. Hemelaere, J. Desroches and J.-F. Paquin, *J. Fluorine Chem.* 2015, **180**, 216.
- [S4] E. M. Simmons and J. F. Hartwig, *Angew. Chem. Int. Ed.* 2012, **51**, 3066.


[S5] J. Vicario, P. Ortiz and F. Palacios, *Eur. J. Org. Chem.* 2013, 7095.

[S6] (a) S. Bugge, S. Kaspersen, S. Larsen, U. Nonstad, G. Björköy, E. Sundby and B. Hoff, *Eur. J. Med. Chem.* 2014, **75**, 354; (b) S. Bugge, S. Kaspersen, E. Sundby and B. Hoff, *Tetrahedron*, 2012, **68**, 9226; (c) S. Bugge, I. Moen, K. Sylte, E. Sundby and B. Hoff, *Eur. J. Med. Chem.* 2015, **94**, 175; (d) J. Schutter, J. Park, C. Leung, P. Gormley, Y. Lin, Z. Hu, A. Berghuis, J. Poirier and Y. Tsantrizos, *J. Med. Chem.*, 2014, **57**, 5764.


9. Characterization data of products



Diphenyl(1-(phenylamino)propyl)phosphine oxide (3aa) (97%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.92 – 7.83 (m, 2H), 7.82 – 7.72 (m, 2H), 7.55 – 7.37 (m, 4H), 7.33 (m, 2H), 7.08 (dd, $J = 8.2, 7.6$ Hz, 2H), 6.65 (t, $J = 7.3$ Hz, 1H), 6.56 (d, $J = 7.9$ Hz, 2H), 4.33 – 4.19 (m, 1H), 4.12 (m, 1H), 2.07 – 1.84 (m, 1H), 1.67 (m, 1H), 0.95 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 147.1, 147.1, 131.9, 131.8, 131.8, 131.7, 131.6, 131.2, 131.2, 131.1, 129.1, 128.6 (d, $J = 11.3$ Hz), 128.3 (d, $J = 11.4$ Hz), 117.78, 113.18, 53.6 (d, $J = 80.1$ Hz), 23.3 (d, $J = 4.3$ Hz), 10.9 (d, $J = 9.8$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 31.71. HRMS calc. for $\text{C}_{21}\text{H}_{22}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 358.1331; found, 358.1334.




(1-(benzylamino)propyl)diphenylphosphine oxide (3ab) (55%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.93 (m, 2H), 7.88 – 7.78 (m, 2H), 7.59 – 7.35 (m, 6H), 7.34 – 7.16 (m, 3H), 7.16 – 7.04 (m, 2H), 3.82 – 3.68 (m, 1H), 3.59 (d, $J = 12.9$ Hz, 1H), 3.36 (m, 1H), 1.92 (m, 1H), 1.60 (m, 2H), 1.00 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 139.6, 133.2, 132.4 (d, $J = 9.5$ Hz), 131.7, 131.6, 131.5, 131.4, 131.2, 131.1, 128.5, 128.4, 128.3, 128.2, 128.1, 127.0, 57.9 (d, $J = 81.9$ Hz), 52.6 (d, $J = 7.9$ Hz), 22.3 (d, $J = 3.8$ Hz), 11.0 (d, $J = 9.7$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 30.82. HRMS calc. for $\text{C}_{22}\text{H}_{24}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 372.1488; found, 372.1491.




(1-(benzyl(methyl)amino)propyl)diphenylphosphine oxide (3ac) (80%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.86 (dd, $J = 27.0, 19.1$ Hz, 2H), 7.75 – 7.59 (m, 2H), 7.58 – 7.40 (m, 3H), 7.33 (t, $J = 7.0$ Hz, 1H), 7.27 – 7.17 (m, 2H), 7.13 (t, $J = 7.7$ Hz, 2H), 6.72 – 6.45 (m, 3H), 4.67 – 4.38 (m, 1H), 2.97 (s, 3H), 2.25 (m, 1H), 1.77 (m, 1H), 0.87 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 150.5 (d, $J = 3.2$ Hz), 132.8, 132.0 (d, $J = 13.2$ Hz), 131.6 (d, $J = 2.6$ Hz), 131.6 (d, $J = 2.7$ Hz), 131.1, 130.9, 130.8, 130.7, 130.6, 128.9, 128.7 (d, $J = 10.9$ Hz), 128.1, 127.9, 116.7, 112.4,


60.5 (d, $J = 76.6$ Hz), 33.0, 19.5 (d, $J = 5.5$ Hz), 11.5 (d, $J = 12.8$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 31.99. HRMS calc. for $\text{C}_{23}\text{H}_{24}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 384.1488; found, 384.1485.



Diphenyl(1-((R)-1-phenylethyl)amino)propylphosphine oxide (3ad) (65%) (d. r. = 1.0 : 1.2) White solid; ^1H NMR (400 MHz, CDCl_3) δ 8.00 – 7.63 (m, 4H), 7.57 – 7.31 (m, 6H), 7.29 – 7.14 (m, 3H), 7.08 (d, $J = 7.0$ Hz, 1H), 7.02 – 6.92 (m, 1H), 3.88 (q, $J = 6.4$ Hz, 0.44H), 3.34 (q, $J = 6.5$ Hz, 0.52H), 3.23 (dd, $J = 11.2, 7.3$ Hz, 1H), 2.50 – 2.08 (m, 1H), 2.03 – 1.81 (m, 0.61H), 1.69 – 1.50 (m, 1H), 1.49 – 1.33 (m, 0.64H), 1.24 (m, 1.54H), 1.10 (m, 1.55H), 0.99 – 0.69 (m, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 144.8, 144.2, 133.3, 132.6, 132.4, 131.5, 131.4, 131.3, 131.2, 131.1, 131.0, 130.9, 128.4, 128.3, 128.2, 128.1, 128.0, 127.2, 127.0, 126.9, 56.5, 56.4, 56.3, 55.5, 55.2, 55.0, 54.3, 53.4, 24.6, 24.0, 23.8, 23.7, 11.0, 10.9, 10.3, 10.2. ^{31}P NMR (162 MHz, CDCl_3) δ 32.82, 30.33. (d. r. = 1 : 1.2). HRMS calc. for $\text{C}_{23}\text{H}_{26}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 386.1644; found, 386.1647.




1-((4-methoxyphenyl)amino)propyl)diphenylphosphine oxide (3ae) (92%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.87 (m, 2H), 7.83 – 7.73 (m, 2H), 7.55 – 7.37 (m, 4H), 7.37 – 7.29 (m, 2H), 6.67 (d, $J = 8.8$ Hz, 2H), 6.52 (t, $J = 6.2$ Hz, 2H), 4.15 (m, 1H), 3.88 (d, $J = 10.2$ Hz, 1H), 3.69 (s, 3H), 2.07 – 1.81 (m, 1H), 1.62 (m, 1H), 0.95 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 152.1, 141.2 (d, $J = 7.8$ Hz), 132.0 (d, $J = 13.4$ Hz), 131.6 (d, $J = 16.5$ Hz), 131.2, 131.1, 131.0, 130.9, 128.6, 128.4, 128.3, 128.1, 55.50, 54.9 (d, $J = 80.3$ Hz), 23.2 (d, $J = 4.3$ Hz), 10.9 (d, $J = 9.7$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 31.61. HRMS calc. for $\text{C}_{22}\text{H}_{24}\text{NO}_2\text{P}$ $[\text{M}+\text{Na}]^+$, 388.1437; found, 388.1435.




Methyl 4-((1-(diphenylphosphoryl)propyl)amino)benzoate (3af) (84%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.94 – 7.82 (m, 2H), 7.80 – 7.68 (m, 4H), 7.62 – 7.44 (m, 3H), 7.37 (t, $J = 7.2$ Hz, 1H), 7.30 (m, 2H), 6.59 (d, $J = 8.8$ Hz, 2H), 5.32 (s, 1H), 4.48 – 4.20 (m, 1H), 3.81 (s, 3H), 1.99 – 1.84 (m, 1H), 1.83 – 1.67 (m, 1H), 0.97 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 166.94, 151.5 (d, $J = 5.5$ Hz), 132.00, 131.97, 131.80, 131.77, 131.53, 131.38, 131.24, 131.03, 130.98, 130.94, 130.89, 130.5 (d, $J = 10.3$ Hz), 128.73, 128.62, 128.3 (d, $J = 11.4$ Hz), 118.4, 111.7, 53.2 (d, $J = 78.9$ Hz), 51.3, 23.1 (d, $J = 4.0$ Hz), 10.8 (d, $J = 10.4$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 31.66. HRMS calc. for $\text{C}_{23}\text{H}_{24}\text{NO}_3\text{P}$ $[\text{M}+\text{Na}]^+$, 416.1386; found,


416.1382.




(1-((4-bromophenyl)amino)propyl)diphenylphosphine oxide (3ag) (98%) White solid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.92 – 7.80 (m, 2H), 7.80 – 7.68 (m, 2H), 7.60 – 7.45 (m, 3H), 7.41 (dd, $J = 10.6, 4.2$ Hz, 1H), 7.33 (m, 2H), 7.18 – 7.07 (m, 2H), 6.44 (d, $J = 8.8$ Hz, 2H), 4.36 (dd, $J = 10.5, 3.8$ Hz, 1H), 4.25 – 4.06 (m, 1H), 2.00 – 1.80 (m, 1H), 1.76 – 1.57 (m, 1H), 0.94 (t, $J = 7.4$ Hz, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 146.4 (d, $J = 6.7$ Hz), 132.0, 131.9, 131.8, 131.7, 131.1, 131.0, 130.8, 130.7, 128.7 (d, $J = 11.3$ Hz), 128.4 (d, $J = 11.4$ Hz), 114.6, 109.1, 53.9 (d, $J = 79.5$ Hz), 23.2 (d, $J = 4.3$ Hz), 10.9 (d, $J = 10.1$ Hz). $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 31.59. HRMS calc. for $\text{C}_{21}\text{H}_{21}\text{BrNOP}$ $[\text{M}+\text{Na}]^+$, 436.0436; found, 436.0432.




(1-(naphthalen-1-ylamino)propyl)diphenylphosphine oxide (3ah) (99%) White solid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.88 (dd, $J = 19.2, 9.3$ Hz, 2H), 7.83 – 7.68 (m, 4H), 7.52 – 7.29 (m, 6H), 7.28 – 7.20 (m, 3H), 7.17 (d, $J = 8.1$ Hz, 1H), 6.64 (d, $J = 7.4$ Hz, 1H), 4.89 (d, $J = 8.6$ Hz, 1H), 4.48 (t, $J = 21.1$ Hz, 1H), 2.18 – 1.95 (m, 1H), 1.80 (m, 1H), 1.05 – 0.89 (m, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 142.1 (d, $J = 7.3$ Hz), 134.28, 131.8 (d, $J = 18.7$ Hz), 131.2, 131.1, 131.0, 130.8 (d, $J = 11.9$ Hz), 128.6, 128.5, 128.4, 128.3, 128.2, 126.1, 125.7, 124.7, 123.3, 119.8, 117.7, 104.8, 53.3 (d, $J = 79.8$ Hz), 23.1 (d, $J = 3.7$ Hz), 10.9 (d, $J = 9.2$ Hz). $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 32.07. HRMS calc. for $\text{C}_{25}\text{H}_{24}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 408.1488; found, 408.1485.




Diphenyl(1-(pyridin-2-ylamino)propyl)phosphine oxide (3ai) (84%) White solid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.01 (d, $J = 4.5$ Hz, 1H), 7.86 (m, 4H), 7.57 – 7.40 (m, 3H), 7.37 – 7.30 (m, 1H), 7.29 – 7.17 (m, 3H), 6.54 – 6.32 (m, 2H), 5.51 (s, 1H), 5.43 – 5.29 (m, 1H), 1.78 (m, 2H), 0.96 (t, $J = 7.3$ Hz, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 157.8 (d, $J = 5.0$ Hz), 147.1, 136.7, 132.5, 132.1, 131.6 (d, $J = 2.4$ Hz), 131.4 (d, $J = 2.6$ Hz), 131.2, 131.1, 131.0, 130.9, 130.8, 128.6, 128.4, 128.0 (d, $J = 11.5$ Hz), 112.72, 109.09, 49.4 (d, $J = 80.2$ Hz), 22.7 (d, $J = 4.8$ Hz), 10.6 (d, $J = 11.1$ Hz). $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 33.65. HRMS calc. for $\text{C}_{20}\text{H}_{21}\text{N}_2\text{OP}$ $[\text{M}+\text{Na}]^+$, 359.1284; found, 359.1289.




diphenyl(1-(quinolin-2-ylamino)propyl)phosphine oxide (3aj) (50%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.92 (dd, $J = 17.6, 9.7$ Hz, 4H), 7.72 (d, $J = 8.4$ Hz, 1H), 7.64 (d, $J = 8.8$ Hz, 1H), 7.57 – 7.43 (m, 5H), 7.27 – 7.09 (m, 4H), 6.67 (d, $J = 8.8$ Hz, 1H), 5.97 (d, $J = 9.0$ Hz, 1H), 5.74 (d, $J = 6.8$ Hz, 1H), 1.84 (dd, $J = 14.6, 7.3$ Hz, 2H), 0.98 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 156.0 (d, $J = 4.4$ Hz), 147.5, 136.7, 132.7, 132.0, 131.8, 131.6 (d, $J = 30.0$ Hz), 131.2, 131.1, 131.0, 130.9, 129.1, 128.6 (d, $J = 11.3$ Hz), 128.0 (d, $J = 11.6$ Hz), 127.3, 126.3, 123.6, 121.9, 112.7, 49.1 (d, $J = 79.8$ Hz), 22.7 (d, $J = 4.2$ Hz), 10.8 (d, $J = 11.0$ Hz) ^{31}P NMR (162 MHz, CDCl_3) δ 34.46. HRMS calc. for $\text{C}_{24}\text{H}_{23}\text{N}_2\text{OP}$ $[\text{M}+\text{H}]^+$, 387.1621; found, 387.1626.




Diphenyl(1-(phenylamino)butyl)phosphine oxide (3ak) (92%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.96 – 7.83 (m, 2H), 7.83 – 7.72 (m, 2H), 7.55 – 7.42 (m, 3H), 7.39 (m, 1H), 7.35 – 7.28 (m, 2H), 7.06 (dd, $J = 8.1, 7.6$ Hz, 2H), 6.68 – 6.57 (m, 1H), 6.53 (d, $J = 8.1$ Hz, 2H), 4.32 (m, 1H), 4.06 (d, $J = 10.2$ Hz, 1H), 1.97 – 1.76 (m, 1H), 1.73 – 1.58 (m, 1H), 1.58 – 1.43 (m, 1H), 1.37 – 1.16 (m, 1H), 0.79 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 147.1 (d, $J = 6.6$ Hz), 131.92, 131.8 (d, $J = 2.8$ Hz), 131.6 (d, $J = 2.6$ Hz), 131.3, 131.2, 131.1, 131.0, 130.8, 129.0, 128.6, 128.5, 128.3, 128.1, 117.7, 113.0, 52.4 (d, $J = 80.5$ Hz), 32.4 (d, $J = 4.2$ Hz), 19.5 (d, $J = 10.1$ Hz), 13.81. ^{31}P NMR (162 MHz, CDCl_3) δ 31.52. HRMS calc. for $\text{C}_{22}\text{H}_{24}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 372.1488; found, 372.1490.




diphenyl(1-(phenylamino)pentyl)phosphine oxide (3al) (60%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.94 – 7.82 (m, 2H), 7.81 – 7.72 (m, 2H), 7.59 – 7.44 (m, 3H), 7.40 (m 1H), 7.32 (m 2H), 7.12 – 6.99 (m, 2H), 6.63 (t, $J = 7.3$ Hz, 1H), 6.52 (d, $J = 7.9$ Hz, 2H), 4.38 – 4.14 (m, 1H), 4.04 (dd, $J = 10.5, 3.5$ Hz, 1H), 2.01 – 1.78 (m, 1H), 1.64 (m, 1H), 1.55 – 1.38 (m, 1H), 1.32 – 1.09 (m, 3H), 0.75 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 147.1 (d, $J = 6.5$ Hz), 132.0, 131.9 (d, $J = 2.8$ Hz), 131.7 (d, $J = 2.7$ Hz), 131.4, 131.3, 131.2, 131.1, 131.0, 130.9, 129.1, 128.7, 128.6, 128.4, 128.2, 117.8, 113.2, 52.6 (d, $J = 80.0$ Hz), 29.9 (d, $J = 4.2$ Hz), 28.3 (d, $J = 9.6$ Hz), 22.5, 13.7. ^{31}P NMR (162 MHz, CDCl_3) δ 31.69. HRMS calc. for $\text{C}_{23}\text{H}_{26}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 386.1644; found, 386.1647.



Diphenyl(1-(phenylamino)hexyl)phosphine oxide (3am) (57%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.91 – 7.82 (m, 2H), 7.82 – 7.72 (m, 2H), 7.59 – 7.43 (m, 3H), 7.43 – 7.36 (m, 1H), 7.32 (m, 2H), 7.12 – 6.99 (m, 2H), 6.63 (t, $J = 7.3$ Hz, 1H), 6.51 (t, $J = 7.4$ Hz, 2H), 4.40 – 4.19 (m, 1H), 4.02 (m, 1H), 2.04 – 1.79 (m, 1H), 1.73 – 1.56 (m, 1H), 1.55 – 1.39 (m, 1H), 1.37 – 1.20 (m, 1H), 1.20 – 1.01 (m, 4H), 0.79 – 0.66 (m, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 147.1 (d, $J = 6.5$ Hz), 132.0, 131.9, 131.7, 131.3 (d, $J = 8.9$ Hz), 131.2 (d, $J = 9.0$ Hz), 131.1, 130.9, 129.1, 128.7, 128.5, 128.3, 128.2, 117.8, 113.2, 52.7 (d, $J = 80.0$ Hz), 31.5, 30.2 (d, $J = 4.1$ Hz), 25.8 (d, $J = 9.6$ Hz), 22.2, 13.8. ^{31}P NMR (162 MHz, CDCl_3) δ 31.61. HRMS calc. for $\text{C}_{24}\text{H}_{28}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 400.1801; found, 400.1797.




Diphenyl(4-phenyl-1-(phenylamino)butyl)phosphine oxide (3an) (99%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.86 – 7.77 (m, 2H), 7.77 – 7.66 (m, 2H), 7.45 (dd, $J = 21.9, 6.2$ Hz, 3H), 7.39 – 7.32 (m, 1H), 7.26 (t, $J = 14.0$ Hz, 2H), 7.13 (m, 3H), 7.04 (t, $J = 7.6$ Hz, 2H), 6.95 (d, $J = 7.1$ Hz, 2H), 6.62 (t, $J = 7.1$ Hz, 1H), 6.51 (d, $J = 7.8$ Hz, 2H), 4.67 – 3.96 (m, 2H), 2.63 – 2.31 (m, 2H), 1.97 – 1.78 (m, 2H), 1.66 (dd, $J = 29.5, 8.7$ Hz, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 147.0 (d, $J = 6.2$ Hz), 141.43, 131.7 (d, $J = 18.1$ Hz), 131.40, 131.27, 131.2 (d, $J = 9.0$ Hz), 131.0 (d, $J = 9.0$ Hz), 130.5 (d, $J = 5.3$ Hz), 129.00, 128.5 (d, $J = 11.3$ Hz), 128.25, 128.13, 128.1 (d, $J = 6.2$ Hz), 125.52, 117.63, 113.02, 52.3 (d, $J = 80.0$ Hz), 35.26, 29.5 (d, $J = 4.4$ Hz), 27.6 (d, $J = 9.7$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 32.16. HRMS calc. for $\text{C}_{28}\text{H}_{28}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 448.1801; found, 448.1807.




(1-((4-bromophenyl)amino)-4-phenylbutyl)diphenylphosphine oxide (3ao) (99%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.87 – 7.76 (m, 2H), 7.72 (dd, $J = 10.6, 7.9$ Hz, 2H), 7.52 (t, $J = 7.3$ Hz, 1H), 7.45 (dd, $J = 10.1, 4.5$ Hz, 2H), 7.38 (t, $J = 7.4$ Hz, 1H), 7.34 – 7.26 (m, 2H), 7.17 (t, $J = 7.2$ Hz, 2H), 7.13 – 7.03 (m, 3H), 6.96 (d, $J = 7.4$ Hz, 2H), 6.38 (d, $J = 8.6$ Hz, 2H), 4.46 (d, $J = 8.4$ Hz, 1H), 4.18 (t, $J = 19.1$ Hz, 1H), 2.58 – 2.33 (m, 2H), 1.94 – 1.79 (m, 2H), 1.71 (dd, $J = 18.2, 9.0$ Hz, 1H), 1.61 (dd, $J = 14.8, 6.9$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 146.2 (d, $J = 5.9$ Hz), 141.3, 131.9 (d, $J = 2.5$ Hz), 131.8 (d, $J = 2.6$ Hz), 131.7, 131.5, 131.3, 131.1, 131.0, 130.9, 130.4 (d, $J = 13.2$ Hz), 128.6 (d, $J = 11.2$ Hz), 128.4, 128.3, 128.1, 125.6, 114.5, 109.0, 52.5 (d, $J = 79.4$ Hz), 35.3, 29.3 (d, $J = 4.2$ Hz), 27.6 (d, $J = 9.9$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 31.68. HRMS calc. for $\text{C}_{28}\text{H}_{27}\text{BrNOP}$ $[\text{M}+\text{Na}]^+$, 526.0906;


found, 526.0912.




Diphenyl(5-phenyl-1-(phenylamino)pentyl)phosphine oxide (3ap) (61%) White solid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.91 – 7.81 (m, 2H), 7.79 – 7.71 (m, 2H), 7.56 – 7.39 (m, 4H), 7.33 (m, 2H), 7.21 (t, $J = 7.3$ Hz, 2H), 7.14 (t, $J = 7.3$ Hz, 1H), 7.04 (dd, $J = 17.2, 7.7$ Hz, 4H), 6.66 (t, $J = 7.3$ Hz, 1H), 6.50 (d, $J = 7.9$ Hz, 2H), 4.37 – 4.17 (m, 1H), 4.08 – 3.87 (m, 1H), 2.58 – 2.36 (m, 2H), 2.03 – 1.80 (m, 1H), 1.75 – 1.60 (m, 1H), 1.58 – 1.40 (m, 3H), 1.38 – 1.24 (m, 1H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 147.1 (d, $J = 6.7$ Hz), 142.3, 132.0, 131.8, 131.4 (d, $J = 9.0$ Hz), 131.2 (d, $J = 9.0$ Hz), 129.2, 128.8, 128.6, 128.4, 128.3, 128.2, 128.1, 125.6, 118.0, 113.3, 52.6 (d, $J = 79.9$ Hz), 35.5, 31.2, 30.1 (d, $J = 4.2$ Hz), 25.9 (d, $J = 9.5$ Hz). $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 31.62. HRMS calc. for $\text{C}_{29}\text{H}_{30}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 462.1957; found, 462.1965.




Diphenyl(1-phenylpiperidin-2-yl)phosphine oxide(3aq) (82%) White solid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.87 (m, 2H), 7.67 (m, 2H), 7.57 – 7.44 (m, 3H), 7.33 (dd, $J = 16.0, 8.5$ Hz, 1H), 7.27 – 7.19 (m, 2H), 7.07 (dd, $J = 8.7, 7.2$ Hz, 2H), 6.65 (t, $J = 7.4$ Hz, 3H), 4.64 (s, 1H), 4.12 – 3.91 (m, 1H), 3.56 (d, $J = 13.3$ Hz, 1H), 2.55 – 2.25 (m, 1H), 2.02 – 1.77 (m, 2H), 1.68 – 1.49 (m, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 150.4 (d, $J = 5.8$ Hz), 133.0, 132.1 (d, $J = 9.8$ Hz), 131.5 (d, $J = 2.7$ Hz), 131.2 (d, $J = 2.7$ Hz), 131.1, 131.0, 130.9, 130.8, 128.9, 128.7, 128.6, 128.1, 127.9, 118.0, 115.8, 56.5 (d, $J = 77.2$ Hz), 45.9, 23.9 (d, $J = 4.2$ Hz), 23.5, 21.0 (d, $J = 1.6$ Hz). $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 33.63. HRMS calc. for $\text{C}_{23}\text{H}_{24}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 384.1488; found, 384.1483.




Diphenyl(1-phenylpyrrolidin-2-yl)phosphine oxide(3ar) (70%) White solid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.97 – 7.85 (m, 2H), 7.77 (dd, $J = 17.1, 8.4$ Hz, 2H), 7.45 (m, 4H), 7.35 – 7.24 (m, 2H), 6.92 (t, $J = 7.6$ Hz, 2H), 6.54 (t, $J = 7.2$ Hz, 1H), 6.34 (d, $J = 8.2$ Hz, 2H), 4.67 (t, $J = 8.9$ Hz, 1H), 3.60 (t, $J = 8.3$ Hz, 1H), 3.19 (m, 1H), 2.43 (dd, $J = 18.7, 12.1$ Hz, 1H), 2.22 – 2.02 (m, 1H), 2.01 – 1.78 (m, 2H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 147.6, 132.0, 131.9, 131.7 (d, $J = 9.0$ Hz), 131.7, 131.5 (d, $J = 8.4$ Hz), 131.0 (d, $J = 21.5$ Hz), 128.6, 128.4, 128.3, 128.1 (d, $J = 11.0$ Hz), 116.7, 113.1, 60.3 (d, $J = 86.6$ Hz), 50.7, 27.6, 24.0. $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 27.50. HRMS calc. for $\text{C}_{22}\text{H}_{22}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 370.1331; found, 370.1335.




1-(2,6-diisopropylphenyl)pyrrolidin-2-yl)diphenylphosphine oxide (3as) (55%) White solid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.59 (m, 2H), 7.36 (m, 5H), 7.24 (dd, $J = 14.0, 6.5$ Hz, 1H), 7.15 – 6.97 (m, 4H), 6.81 – 6.64 (m, 1H), 4.52 (m, 1H), 3.71 – 3.49 (m, 2H), 3.21 – 2.95 (m, 2H), 2.52 – 2.19 (m, 3H), 2.05 – 1.88 (m, 1H), 1.47 (d, $J = 6.8$ Hz, 3H), 1.22 (d, $J = 6.8$ Hz, 3H), 1.01 (d, $J = 6.8$ Hz, 3H), 0.36 (d, $J = 6.8$ Hz, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 150.6, 146.4, 143.4, 131.1, 131.0, 130.9, 130.5, 130.4, 128.4, 128.3, 127.9, 127.8, 126.6, 124.4, 123.4, 62.7, 61.8, 56.9, 28.1, 28.0, 27.3, 26.7, 26.1, 25.7, 23.6, 21.6. $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 28.39. HRMS calc. for $\text{C}_{28}\text{H}_{34}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 454.2270; found, 454.2274.




Diphenyl(1-(phenylamino)heptyl)phosphine oxide (3ax) (63%) White solid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.92 – 7.82 (m, 2H), 7.81 – 7.71 (m, 2H), 7.58 – 7.43 (m, 3H), 7.43 – 7.36 (m, 1H), 7.32 (m, 2H), 7.12 – 7.00 (m, 2H), 6.62 (dd, $J = 17.9, 10.6$ Hz, 1H), 6.50 (dd, $J = 16.4, 5.4$ Hz, 2H), 4.36 (d, $J = 68.9$ Hz, 1H), 4.08 (s, 1H), 2.00 – 1.79 (m, 1H), 1.79 – 1.57 (m, 1H), 1.57 – 1.42 (m, 1H), 1.27 (d, $J = 9.1$ Hz, 1H), 1.10 (m, 6H), 0.78 (t, $J = 7.0$ Hz, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 147.1 (d, $J = 6.6$ Hz), 131.9 (d, $J = 2.8$ Hz), 131.8, 131.7 (d, $J = 2.7$ Hz), 131.3 (d, $J = 9.0$ Hz), 131.2 (d, $J = 8.9$ Hz), 131.0, 129.1, 128.6 (d, $J = 11.2$ Hz), 128.3 (d, $J = 11.3$ Hz), 117.7, 113.1, 52.6 (d, $J = 80.1$ Hz), 31.4, 30.2 (d, $J = 4.2$ Hz), 29.0, 26.1 (d, $J = 9.6$ Hz), 22.4, 13.9. $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 31.76. HRMS calc. for $\text{C}_{25}\text{H}_{30}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 414.1957; found, 414.1963.




Bis(4-methoxyphenyl)(1-(phenylamino)propyl)phosphine oxide (3ba) (94%) White solid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.77 (dd, $J = 10.2, 8.8$ Hz, 2H), 7.68 (dd, $J = 10.2, 8.9$ Hz, 2H), 7.09 (t, $J = 7.7$ Hz, 2H), 6.97 (d, $J = 7.0$ Hz, 2H), 6.85 (d, $J = 7.1$ Hz, 2H), 6.65 (t, $J = 7.3$ Hz, 1H), 6.56 (d, $J = 8.0$ Hz, 2H), 4.20 – 4.03 (m, 2H), 3.81 (s, 3H), 3.74 (s, 3H), 2.11 – 1.84 (m, 1H), 1.75 – 1.43 (m, 1H), 0.90 (dt, $J = 9.3, 7.0$ Hz, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 162.2 (d, $J = 2.7$ Hz), 162.10 (d, $J = 2.8$ Hz), 147.2, 147.1, 133.1, 133.0, 132.9, 132.8, 129.1, 123.2 (d, $J = 11.7$ Hz), 122.2 (d, $J = 8.8$ Hz), 117.6, 114.1, 114.0, 113.9, 113.8, 113.1, 55.1, 55.1, 53.7 (d, $J = 81.3$ Hz), 23.3 (d, $J = 4.2$ Hz), 10.9 (d, $J = 9.7$ Hz). $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 31.89. HRMS calc. for $\text{C}_{23}\text{H}_{26}\text{NO}_3\text{P}$ $[\text{M}+\text{Na}]^+$, 418.1543; found, 418.1540.



(1-(phenylamino)propyl)bis(4-(trifluoromethyl)phenyl)phosphine oxide (3ca) (52%) White solid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.02 (dd, $J = 19.0, 9.0$ Hz, 2H), 7.91 (dd, $J = 19.0, 8.7$ Hz, 2H), 7.78 (t, $J = 10.0$ Hz, 2H), 7.59 (t, $J = 13.8$ Hz, 2H), 7.09 (t, $J = 7.9$ Hz, 2H), 6.68 (dd, $J = 16.4, 9.1$ Hz, 1H), 6.57 (d, $J = 8.0$ Hz, 2H), 4.45 – 4.24 (m, 1H), 4.23 – 3.99 (m, 1H), 2.08 – 1.86 (m, 1H), 1.81 – 1.57 (m, 1H), 1.00 (t, $J = 7.4$ Hz, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 146.8 (d, $J = 6.9$ Hz), 135.8 (d, $J = 21.2$ Hz), 134.9 (d, $J = 26.6$ Hz), 134.3, 134.0, 133.7, 131.8, 131.7, 131.6, 129.3, 125.7, 125.6, 125.4, 125.3, 124.7, 122.0, 118.7, 113.6, 54.2 (d, $J = 80.8$ Hz), 23.3 (d, $J = 4.4$ Hz), 10.8 (d, $J = 10.3$ Hz). $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 29.51. $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -63.31, -63.41. **HRMS** calc. for $\text{C}_{23}\text{H}_{20}\text{F}_6\text{NOP}$ $[\text{M}+\text{Na}]^+$, 494.1079; found, 494.1082.




(1-(phenylamino)propyl)di-o-tolylphosphine oxide (3da) (40%) White solid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.91 (m, 1H), 7.66 – 7.55 (m, 1H), 7.45 – 7.38 (m, 1H), 7.35 – 7.26 (m, 2H), 7.17 (t, $J = 7.9$ Hz, 3H), 7.10 (dd, $J = 11.1, 5.6$ Hz, 2H), 6.75 – 6.63 (m, 3H), 4.59 (m, 1H), 4.54 – 4.39 (m, 1H), 2.26 (d, $J = 6.3$ Hz, 2H), 1.94 – 1.75 (m, 1H), 1.71 – 1.55 (m, 1H), 0.96 – 0.85 (m, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 146.7 (d, $J = 8.3$ Hz), 142.5 (d, $J = 7.7$ Hz), 140.9, 132.9 (d, $J = 9.4$ Hz), 132.0, 131.9, 131.7 (d, $J = 2.6$ Hz), 131.6, 131.5 (d, $J = 4.8$ Hz), 131.4, 130.9, 130.0 (d, $J = 5.6$ Hz), 129.4, 129.2, 125.8 (d, $J = 11.2$ Hz), 125.5 (d, $J = 11.7$ Hz), 117.9, 117.6, 113.8, 113.1, 50.8 (d, $J = 78.5$ Hz), 23.3 (d, $J = 4.9$ Hz), 21.2 (d, $J = 3.9$ Hz), 21.0 (d, $J = 4.6$ Hz), 10.8 (d, $J = 8.6$ Hz). $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 35.59. **HRMS** calc. for $\text{C}_{23}\text{H}_{26}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 386.1644; found, 386.1641.




Bis(2-isopropylphenyl)(1-(phenylamino)propyl)phosphine oxide (3ea) (56%) White solid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.08 – 7.84 (m, 1H), 7.61 – 7.52 (m, 1H), 7.47 (d, $J = 7.5$ Hz, 1H), 7.41 – 7.27 (m, 4H), 7.20 (t, $J = 7.9$ Hz, 2H), 7.13 – 6.98 (m, 1H), 6.72 (m, 3H), 4.72 (dd, $J = 10.4, 5.8$ Hz, 1H), 4.55 – 4.35 (m, 1H), 3.57 (m, 1H), 3.43 – 3.20 (m, 1H), 1.93 – 1.75 (m, 1H), 1.65 (m, 1H), 1.16 (dd, $J = 6.7, 4.8$ Hz, 6H), 0.93 (t, $J = 7.4$ Hz, 3H), 0.70 (d, $J = 6.6$ Hz, 3H), 0.52 (d, $J = 6.8$ Hz, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 153.9 (d, $J = 8.2$ Hz), 151.8 (d, $J = 10.1$ Hz), 146.8 (d, $J = 8.8$ Hz),


132.5, 132.4, 132.1 (d, $J = 2.6$ Hz), 131.9 (d, $J = 2.5$ Hz), 131.2, 130.8, 130.5 (d, $J = 11.2$ Hz), 130.2, 129.9, 129.4, 127.5, 127.4, 126.7 (d, $J = 10.4$ Hz), 126.0, 125.9, 125.5 (d, $J = 11.7$ Hz), 117.6, 113.1, 51.2 (d, $J = 79.1$ Hz), 30.9 (d, $J = 5.2$ Hz), 24.3, 23.8, 23.4, 23.3, 23.2, 22.8, 10.6 (d, $J = 8.5$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 35.66. HRMS calc. for $\text{C}_{27}\text{H}_{34}\text{NOP}$ $[\text{M}+\text{Na}]^+$, 442.2270; found, 442.2266.




diethyl (1-(4-methylphenylsulfonamido)propyl)phosphonate (6aa) (91%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.79 (d, $J = 8.2$ Hz, 2H), 7.28 (d, $J = 8.1$ Hz, 2H), 6.16 – 5.82 (m, 1H), 4.15 – 3.88 (m, 4H), 3.61 (m, 1H), 2.41 (s, 3H), 1.88 – 1.66 (m, 1H), 1.62 – 1.42 (m, 1H), 1.26 (m, 6H), 0.84 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 143.0, 138.7, 129.3, 126.9, 63.1, 63.1, 62.3, 62.2, 51.5 (d, $J = 147.2$ Hz), 23.6, 23.6, 21.4, 16.3, 16.3, 16.2, 10.3, 10.2. ^{31}P NMR (162 MHz, CDCl_3) δ 23.54. MS : m/z (M+H): 350.1766.



dimethyl (1-(4-methylphenylsulfonamido)propyl)phosphonate (6ab) (70%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.77 (d, $J = 8.3$ Hz, 2H), 7.42 – 7.17 (m, 2H), 5.48 (d, $J = 6.6$ Hz, 1H), 3.63 (m, 7H), 2.42 (s, 3H), 1.81 – 1.68 (m, 1H), 1.64 – 1.48 (m, 1H), 0.86 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 143.3, 138.4, 129.5, 127.0, 53.6, 53.5, 52.9 (d, $J = 7.0$ Hz), 51.2 (d, $J = 157.3$ Hz), 23.8, 23.8, 21.5, 10.2 (d, $J = 10.1$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 26.03. MS : m/z (M+H): 322.1411.




dibutyl (1-(4-methylphenylsulfonamido)propyl)phosphonate (6ac) (67%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.78 (d, $J = 8.3$ Hz, 2H), 7.27 (d, $J = 8.4$ Hz, 2H), 5.81 (dd, $J = 9.4, 2.9$ Hz, 1H), 4.11 – 3.82 (m, 4H), 3.76 – 3.49 (m, 1H), 2.41 (s, 3H), 1.75 (m, 1H), 1.69 – 1.50 (m, 5H), 1.34 (m, 2H), 0.98 – 0.73 (m, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 143.0, 138.7, 129.4, 126.9, 66.8 (d, $J = 7.4$ Hz), 66.0 (d, $J = 7.3$ Hz), 51.6 (d, $J = 157.4$ Hz), 32.5 (d, $J = 5.5$ Hz), 32.4 (d, $J = 5.8$ Hz), 23.81 (d, $J = 3.0$ Hz), 21.40, 18.6 (d, $J = 2.5$ Hz), 13.5 (d, $J = 2.8$ Hz), 10.2 (d, $J = 9.6$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 23.56. MS : m/z (M+H): 406.2437.




dibenzyl (1-(4-methylphenylsulfonamido)propyl)phosphonate (6ad) (86%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.76 (d, $J = 8.2$ Hz, 2H), 7.38 – 7.28 (m, 6H),


7.24 (m, 4H), 7.18 (d, $J = 8.1$ Hz, 2H), 5.87 (dd, $J = 9.6, 2.8$ Hz, 1H), 5.07 – 4.72 (m, 4H), 3.85 – 3.58 (m, 1H), 2.34 (s, 3H), 1.78 (m, 1H), 1.67 – 1.47 (m, 1H), 0.85 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 143.1, 138.5, 136.1, 136.0, 135.8, 129.4, 128.6, 128.51, 128.5, 128.4, 128.1, 128.0, 127.0, 68.4 (d, $J = 7.3$ Hz), 67.8 (d, $J = 7.1$ Hz), 51.9 (d, $J = 157.4$ Hz), 23.8, 21.4, 10.2 (d, $J = 10.5$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 24.67. MS : m/z (M+H): 474.2138.




***N*-(1-(diphenylphosphoryl)propyl)-4-methylbenzenesulfonamide (6ae)** (65%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 7.97 – 7.69 (m, 4H), 7.64 – 7.40 (m, 7H), 7.30 (t, $J = 14.2$ Hz, 2H), 7.02 (d, $J = 7.8$ Hz, 2H), 4.39 (d, $J = 8.4$ Hz, 1H), 2.33 (s, 3H), 1.62 (m, 2H), 0.85 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 142.34, 139.26, 131.95, 131.92, 131.73, 131.60, 131.57, 131.3 (d, $J = 9.1$ Hz), 131.1, 130.9 (d, $J = 9.0$ Hz), 130.8, 130.2, 129.1, 128.7 (d, $J = 11.4$ Hz), 128.4 (d, $J = 11.8$ Hz), 126.64, 53.9 (d, $J = 79.4$ Hz), 23.0 (d, $J = 3.9$ Hz), 21.39, 10.8 (d, $J = 9.1$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 32.11. MS : m/z (M+H): 414.1887.




diethyl (1-(methylsulfonamido)propyl)phosphonate (6af) (90%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 5.17 (d, $J = 7.6$ Hz, 1H), 4.31 – 4.06 (m, 4H), 3.78 – 3.56 (m, 1H), 3.07 (s, 3H), 1.92 (m, 1H), 1.64 (m, 1H), 1.36 (m, 6H), 1.10 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 62.8 (d, $J = 7.1$ Hz), 62.6 (d, $J = 7.0$ Hz), 52.0 (d, $J = 157.8$ Hz), 42.3, 24.01, 23.98, 16.49, 16.45, 16.43, 16.40, 10.4 (d, $J = 11.7$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 23.91. MS : m/z (M+H): 274.1386.



diethyl (1-((diphenylphosphoryl)amino)propyl)phosphonate (6ag) (87%) White solid; ^1H NMR (400 MHz, CDCl_3) δ 8.01 – 7.80 (m, 4H), 7.58 – 7.36 (m, 6H), 4.23 – 4.00 (m, 4H), 3.55 – 3.25 (m, 2H), 1.91 (m, 1H), 1.81 – 1.66 (m, 1H), 1.30 (m, 6H), 1.06 (t, $J = 7.5$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 133.6, 132.4 (d, $J = 9.9$ Hz), 132.3, 131.9, 131.8, 131.7, 131.0, 128.4 (d, $J = 5.6$ Hz), 128.3 (d, $J = 5.7$ Hz), 62.3 (d, $J = 7.2$ Hz), 62.2 (d, $J = 7.0$ Hz), 49.8, 48.3, 25.6, 16.4 (d, $J = 3.0$ Hz), 16.3 (d, $J = 3.0$ Hz), 10.2 (d, $J = 8.8$ Hz). ^{31}P NMR (162 MHz, CDCl_3) δ 26.22, 26.04, 24.00, 23.82. MS : m/z (M+H): 396.2126.




diethyl (1-((S)-1,1-dimethylethylsulfonamido)propyl)phosphonate (6ah) (82%) (d. r. = 1.0 : 1.0) colourless liquid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 4.30 – 4.03 (m, 8H), 3.80 (t, $J = 7.6$ Hz, 1H), 3.42 (m 3H), 2.04 (m, 1H), 1.90 (m, 1H), 1.76 (m, 2H), 1.39 – 1.29 (m, 12H), 1.25 (s, 18H), 1.14 (t, $J = 7.4$ Hz, 3H), 1.09 – 1.01 (m, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 63.0, 62.9, 62.3 (d, $J = 7.0$ Hz), 62.2, 62.1 (d, $J = 2.1$ Hz), 56.6, 56.5, 56.4, 54.9, 53.3 (d, $J = 150.7$ Hz), 24.6 (d, $J = 2.6$ Hz), 24.3, 22.5, 22.4, 16.4, 16.3 (d, $J = 5.8$ Hz), 16.2 (d, $J = 5.4$ Hz), 16.2, 10.6 (d, $J = 9.7$ Hz), 10.5 (d, $J = 10.9$ Hz). $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 25.43, 24.56, (d. r. = 1.0 : 1.0). **MS : m/z (M+H):** 300.1921.





Diethyl (1-(((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methylsulfonamido)propyl)phosphonate (6ai) (74%) (d. r. = 1.0 : 0.8) colourless liquid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 6.03 (dd, $J = 9.8, 4.4$ Hz, 1H), 5.50 (dd, $J = 9.6, 2.7$ Hz, 0.80H), 4.28 – 4.05 (m, 7.4H), 3.95 (d, $J = 15.0$ Hz, 1H), 3.77 (m, 1.85H), 3.60 (d, $J = 15.0$ Hz, 1H), 3.18 – 2.97 (m, 0.83H), 2.47 – 2.28 (m, 1.84H), 2.21 – 1.99 (m, 2.82H), 1.98 – 1.79 (m, 7.30H), 1.78 – 1.53 (m, 4.57H), 1.50 – 1.39 (m, 1.96H), 1.35 (m, 1.97H), 1.10 (m, 11H), 1.03 (s, 3H), 0.96 (s, 3H), 0.92 (d, $J = 7.0$ Hz, 2.49H). $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 24.37, 23.87, (d. r. = 1.0 : 0.8).


$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 5.98 (dd, $J = 9.7, 4.4$ Hz, 1H), 4.25 – 4.08 (m, 4H), 3.96 (d, $J = 15.0$ Hz, 1H), 3.84 – 3.68 (m, 1H), 3.09 (d, $J = 15.0$ Hz, 1H), 2.40 (d, $J = 19.2$ Hz, 1H), 2.20 – 1.98 (m, 4H), 1.96 – 1.85 (m, 2H), 1.69 – 1.53 (m, 1H), 1.45 (m, 1H), 1.34 (m, 6H), 1.10 (t, $J = 7.3$ Hz, 3H), 1.02 (s, 3H), 0.96 (s, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 216.4, 62.4 (d, $J = 6.9$ Hz), 59.73, 53.13, 52.96, 51.61, 48.72, 42.9 (d, $J = 13.7$ Hz), 27.5, 27.0, 24.5 (d, $J = 2.9$ Hz), 20.05, 19.51, 16.4 (dd, $J = 5.7, 2.6$ Hz), 10.5 (d, $J = 11.8$ Hz). $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 24.38, (d. r. > 20 : 1). **MS : m/z (M+H):** 410.1945.



Diethyl (1-(4-methylphenylsulfonamido)hex-2-en-1-yl)phosphonate (6aj) (18%) White solid; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.77 (d, $J = 8.3$ Hz, 2H), 7.28 (d, $J = 7.9$ Hz, 2H), 5.46 (dd, $J = 9.5, 3.2$ Hz, 1H), 4.21 – 3.92 (m, 4H), 3.72 – 3.52 (m, 1H), 2.41 (s, 3H), 1.68 (m, 1H), 1.56 – 1.42 (m, 1H), 1.26 (m, 7H), 1.13 (d, $J = 7.2$ Hz, 5H), 0.80 (t, $J = 6.9$ Hz, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 143.21, 138.57, 129.42, 127.03, 63.1 (d, $J = 7.2$ Hz), 62.4 (d, $J = 7.0$ Hz), 51.2, 49.6, 31.3, 30.6 (d, $J = 3.0$ Hz), 25.2 (d, $J = 9.7$ Hz), 22.2, 21.4, 16.3 (dd, $J = 9.1, 5.7$ Hz), 13.83. $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 23.73. **MS : m/z (M+H):** 392.1817.


10. Copies of NMR spectra











7.958
7.941
7.937
7.932
7.915
7.911
7.912
7.901
7.891
7.846
7.829
7.825
7.810
7.771
7.770
7.462
7.452
7.443
7.435
7.426
7.425
7.259
7.252
7.233
7.214
7.222
7.118
7.103



3.741
3.709
3.609
3.576
3.388
3.377
3.362
3.361
3.357
3.352
3.341
3.341
3.270
3.239
3.239
3.221
3.214
3.003
2.977
2.866
1.979
1.968
1.648
1.629
1.620
1.573
1.554
1.535
1.017
0.998
0.980
































































31.689
































31.612
























— 28.377






























— 35.576



































5.178
5.159



4.221
4.203
4.187
4.167
4.150
4.130
3.713
3.702
3.678
3.672
3.654
3.647
3.625
3.613
3.074



1.968
1.950
1.940
1.922
1.913
1.894
1.886
1.863
1.853
1.834
1.616
1.616
1.379
1.355
1.318
1.096
1.077



















— 24.378



216.42

